Hammond R, Kloprogge F, Pasqua O, Gillespie S
Front Antibiot. 2025; 1():928365.
PMID: 39816411
PMC: 11732046.
DOI: 10.3389/frabi.2022.928365.
Wang N, Meng F, Deng L, Wu L, Yang Y, Li H
Emerg Microbes Infect. 2025; 14(1):2447607.
PMID: 39745172
PMC: 11721771.
DOI: 10.1080/22221751.2024.2447607.
Siedentop B, Kachalov V, Witzany C, Egger M, Kouyos R, Bonhoeffer S
Elife. 2024; 13.
PMID: 39704726
PMC: 11661791.
DOI: 10.7554/eLife.93740.
Kwak N, Kim J, Kim H, Kwon B, Lee J, Mok J
Tuberc Respir Dis (Seoul). 2024; 88(1):170-180.
PMID: 39343425
PMC: 11704738.
DOI: 10.4046/trd.2024.0099.
Yates T, Barnes S, Dedicoat M, Kon O, Kunst H, Lipman M
Bull World Health Organ. 2024; 102(9):657-664.
PMID: 39219765
PMC: 11362690.
DOI: 10.2471/BLT.23.290948.
The many dimensions of combination therapy: How to combine antibiotics to limit resistance evolution.
Nyhoegen C, Bonhoeffer S, Uecker H
Evol Appl. 2024; 17(8):e13764.
PMID: 39100751
PMC: 11297101.
DOI: 10.1111/eva.13764.
Target regimen profiles for tuberculosis treatment.
Lienhardt C, Dooley K, Nahid P, Wells C, Ryckman T, Kendall E
Bull World Health Organ. 2024; 102(8):600-607.
PMID: 39070602
PMC: 11276158.
DOI: 10.2471/BLT.24.291881.
Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial.
Snobre J, Gasana J, Ngabonziza J, Cuella-Martin I, Rigouts L, Jacobs B
BMJ Open. 2024; 14(7):e078379.
PMID: 39053960
PMC: 11284928.
DOI: 10.1136/bmjopen-2023-078379.
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.
Dartois V, Dick T
Nat Rev Drug Discov. 2024; 23(5):381-403.
PMID: 38418662
PMC: 11078618.
DOI: 10.1038/s41573-024-00897-5.
How We Treat Drug-Susceptible Pulmonary Tuberculosis: A Practical Guide for Clinicians.
Riccardi N, Occhineri S, Vanino E, Antonello R, Pontarelli A, Saluzzo F
Antibiotics (Basel). 2023; 12(12).
PMID: 38136767
PMC: 10740448.
DOI: 10.3390/antibiotics12121733.
Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide.
Krug S, Gupta M, Kumar P, Feller L, Ihms E, Kang B
Nat Commun. 2023; 14(1):8161.
PMID: 38071218
PMC: 10710439.
DOI: 10.1038/s41467-023-43937-1.
Tuberculosis in Spain: An opinion paper.
Moreno Guillen S, Rodriguez-Artalejo F, Ruiz-Galiana J, Canton R, De Lucas Ramos P, Garcia-Botella A
Rev Esp Quimioter. 2023; 36(6):562-583.
PMID: 37922367
PMC: 10710671.
DOI: 10.37201/req/115.2023.
An Overview of Various Rifampicin Analogs against and their Drug Interactions.
Asif M, Qusty N, Alghamdi S
Med Chem. 2023; 20(3):268-292.
PMID: 37855280
DOI: 10.2174/0115734064260853230926080134.
Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.
Ganapathy U, Lan T, Dartois V, Aldrich C, Dick T
Microbiol Spectr. 2023; :e0190023.
PMID: 37681986
PMC: 10580999.
DOI: 10.1128/spectrum.01900-23.
A half-century of research on tuberculosis: Successes and challenges.
Bloom B
J Exp Med. 2023; 220(9).
PMID: 37552470
PMC: 10407785.
DOI: 10.1084/jem.20230859.
The Relative Positioning of Genotyping and Phenotyping for Tuberculosis Resistance Screening in Two EU National Reference Laboratories in 2023.
Anthony R, Groenheit R, Mansjo M, de Zwaan R, Werngren J
Microorganisms. 2023; 11(7).
PMID: 37512981
PMC: 10383358.
DOI: 10.3390/microorganisms11071809.
ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant in caseum surrogate.
Xie M, Ganapathy U, Lan T, Osiecki P, Sarathy J, Dartois V
Antimicrob Agents Chemother. 2023; 67(9):e0038123.
PMID: 37493373
PMC: 10508146.
DOI: 10.1128/aac.00381-23.
Innovative Integrated Motivational Interviewing for Dual Management in Tuberculosis Patients with Diabetes (MID-DOT) in Malaysia.
Mohd Z, Ahmad S, Yaacob N, Mohd Shariff N, Jaeb M, Hussin Z
Healthcare (Basel). 2023; 11(13).
PMID: 37444763
PMC: 10341500.
DOI: 10.3390/healthcare11131929.
Prevalence of mutations associated with isoniazid and rifampicin resistance: A systematic review and -analysis.
Rostamian M, Kooti S, Abiri R, Khazayel S, Kadivarian S, Borji S
J Clin Tuberc Other Mycobact Dis. 2023; 32:100379.
PMID: 37389010
PMC: 10302537.
DOI: 10.1016/j.jctube.2023.100379.
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
Feng Z, Miao Y, Peng Y, Sun F, Zhang Y, Li R
BMC Infect Dis. 2023; 23(1):300.
PMID: 37158831
PMC: 10165810.
DOI: 10.1186/s12879-023-08264-2.
